Abstract
The natriuretic peptides, specifically atrial natriuretic peptide (ANP), are increasingly recognized to play a fundamental role in blood pressure (BP) regulation. This role in BP regulation reflects the pluripotent cardiorenal actions of ANP, which include diuresis, enhancement of renal blood flow and glomerular filtration rate, systemic vasodilatation, suppression of aldosterone, and inhibition of the sympathetic nervous system. These actions of ANP, in addition to recent human studies demonstrating an association of higher plasma ANP with lower risk of hypertension, support the development of an ANP-based therapy for hypertension. M-ANP is a novel ANP-based peptide that is resistant to proteolytic degradation and possesses greater BP-lowering, renal function–enhancing, and aldosterone-suppressing properties than native ANP. In an animal model of hypertension, M-ANP lowers BP via multiple mechanisms, including vasodilatation, diuresis, and inhibition of aldosterone. Importantly, M-ANP enhances both glomerular filtration rate and renal blood flow despite reductions in BP. The pluripotent BP-lowering actions and concomitant enhancement of renal function associated with M-ANP are highly attractive characteristics for an antihypertensive agent and underscore the therapeutic potential of M-ANP. M-ANP currently is heading into clinical testing, which may advance this novel strategy for human hypertension.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease. Lancet. 2008;371(9623):1513–8.
Ong KL, Cheung BMY, Man YB, Lau CP, Lam KSL. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49(1):69–75.
Kaplan NM. Resistant hypertension. J Hypertens. 2005;23(8):1441–4.
Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52(22):1749–57.
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510–26.
de Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science (New York, NY). 1985;230(4727):767–70.
Hosoda K, Nakao K, Mukoyama M, Saito Y, Jougasaki M, Shirakami G, et al. Expression of brain natriuretic peptide gene in human heart. Production in the ventricle. Hypertension. 1991;17(6 Pt 2):1152–5.
Suga S, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 1992;130(1):229–39.
Stingo AJ, Clavell A, Pitelkow M, Heubelin D, Burnett Jr JC. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol. 1992;263(4 Pt 2):H1318–21.
Suga S, Nakao K, Itoh H, Komatsu Y, Ogawa Y, Hama N, et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of “vascular natriuretic peptide system”. J Clin Invest. 1992;90(3):1145–9.
• Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009;(191):341-66. This well-written review provides an overview of the natriuretic peptides, the natriuretic peptide receptors, and the biologic actions of the natriuretic peptides.
Burnett Jr JC, Granger JP, Opgenorth TF. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol. 1984;247:F863–6.
Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78(5):1362–74.
Kasama S, Furuya M, Toyama T, Ichikawa S, Kurabayashi M. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J. 2008;29(12):1485–94.
Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 1990;168(2):863–70.
Clavell A, Stingo A, Heublein D, Burnett JC Jr. C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol 1993:1104–6.
Rubattu S, Sciarretta S, Morriello A, Calvieri C, Battistoni A, Volpe M. NPR-C: a component of the natriuretic peptide familywith implications in human diseases. J Mol Med. 2010;88:889–97.
Anand-Srivastava MB. Natriuretic peptide receptor-C signalling and regulation. Peptides. 2005;26:1044–59.
Huntley BK, Sandberg SM, Noser JA, Cataliotti A, Redfield MM, Matsuda Jr Y, Burnett JC. BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. J Cell Physiol. 2006;209:943–9.
Sangaralingham SJ, Huntley BK, Martin FL, McKie PM, Bellavia D, Ichiki T, Harders GE, Chen HH, Burnett JC. The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic peptide. Hypertension. 2011;57(2):201–7.
Field LJ, Veress AT, Steinhelper ME, Cochrane K, Sonnenberg H. Kidney function in ANF-transgenic mice: effect of blood volume expansion. Am J Physiol. 1991;260(1 Pt 2):R1–5.
John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science (New York, NY). 1995;267(5198):679–81.
Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378(6552):65–8.
Holtwick R, Gotthardt M, Skryabin B, et al. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci U S A. 2002;99:7142–7.
Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41(6):666–76.
• Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009;41(3):348–53. This original research article describes how common genetic variants at the NPPA-NPPB locus, found to be associated with circulating natriuretic peptide concentrations, contribute to interindividual variation in blood pressure and hypertension.
Cannone V, Boerrigter G, Cataliotti A, Costello-Boerrigter LC, Olson TM, McKie PM, Heublein DM, Lahr BD, Bailey KR, Averna M, Redfield MM, Rodeheffer RJ, Burnett Jr JC. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol. 2011;58:629–36.
Sengenes C, Bouloumie A, Hauner H, et al. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem. 2003;278:48617–26.
Tsukamoto O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol. 2009;53:2070–7.
Moro C, Pillard F, de Glisezinski I, et al. Atrial natriuretic peptide contribution to lipid mobilization and utilization during head-down bed rest in humans. Am J Physiol Regul Integr Comp Physiol. 2007;293:R612–7.
Cataliotti A, Macharet F, McKie PM, Rodeheffer RJ, Malatino LS, Bailey KR, et al. Early stages of hypertension are characterized by a deficiency of the cardioprotective hormone BNP. Eur Heart J. 2010;31:244.
Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A. 2000;97(8):4239–44. doi:10.1073/pnas.070371497.
Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett Jr JC. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52:60–8.
Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, Burnett Jr JC. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol. 2009;49(6):668–73.
Hodgson-Zingman DM, Karst ML, Zingman LV, Heublein DM, Darbar D, Herron KJ, et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N Engl J Med. 2008;359(2):158–65.
Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291(Pt 1):83–8.
Lafferty HM, Gunning M, Silva P, Zimmerman MB, Brenner BM, Anderson S. Enkephalinase inhibition increases plasma atrial natriuretic peptide levels, glomerular filtration rate, and urinary sodium excretion in rats with reduced renal mass. Circ Res. 1989;65(3):640–6.
Dickey J, Potter L. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. J Mol Cell Cardiol. 2011;51:67–71.
Chen HH, Lainchbury JG, Burnett Jr JC. Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J Am Coll Cardiol. 2002;40(6):1186–91.
• McKie PM, Cataliotti A, Huntley BK, Martin FL, Olson TM, Burnett JC Jr. A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol 2009;54(11):1024–32. This original research compares the in vitro and in vivo cardiorenal and neurohumoral actions of M-ANP and ANP in normal canines.
• Dickey DM, Yoder AR, Potter LR. A familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation. J Biol Chem 2009;284(29):19196–202. This in vitro study measured the ability of M-ANP to interact with natriuretic peptide receptors and to be proteolytically degraded by neutral endopeptidase.
Ralat L, Guo Q, Ren M, Funke T, Dickey D, Potter L, Tang WJ. Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response. J Biol Chem. 2011;286:4670–9.
• McKie PM, Cataliotti A, Boerrigter G, Chen HH, Sangaralingham SJ, Martin FL, et al. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension 2010;56(6):1152–9. This in vivo study describes the cardiorenal actions of M-ANP compared with BNP in a model of acute hypertension.
Pidgeon GB, Richards AM, Nicholls MG, Espiner EA, Yandle TG, Frampton C. Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension. Hypertension. 1996;27(4):906–13.
Chen HH, Cataliotti A, Schirger JA, Martin FL, Burnett Jr JC. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol. 2005;288(5):R1093–7.
Cataliotti A, Schirger JA, Martin FL, Chen HH, McKie PM, Boerrigter G, et al. Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation. 2005;112(6):836–40.
Chen HH, Grantham JA, Schirger JA, Jougasaki M, Redfield MM, Burnett Jr JC. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Card. 2000;36(5):1706–12.
Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett Jr JC. Maximizing the renal cyclic 3′-5′-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. J Am Soc Nephrol. 2006;17(10):2742–7.
Chen HH, Lainchbury JG, Harty GJ, Burnett Jr JC. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation. 2002;105(8):999–1003.
Chen HH, Redfield MM, Nordstrom LJ, Horton DP, Burnett Jr JC. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail. 2004;10(2):115–9.
Chen HH, Schirger JA, Cataliotti A, Burnett Jr JC. Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure. Eur J Card. 2006;8(7):681–6.
Leader B, Baca Q, Golan D. Protein therapeutics: a summary and pharmacological classification. Nature Reviews: Drug Disc. 2008;7:28–41.
Ozdemir V, Williams Jones B, Glatt S, Tsuang M, Lohr J, Reist C. Theragnostics: Shifting emphasis from pharmacogenomics to theragnostics. Nat Biotechnol 2006;8:242-250.
Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J. 2008;72(11):1787–93.
Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol. 2001;37(7):1820–6.
Morikawa S, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol. 2009;53(12):1040–6.
de Bold AJ. Cardiac natriuretic peptides: gaining further insights into structure-function relationships. J Am Coll Cardiol. 2009;54(11):1033–4.
Kitiyakara C, Guzman NJ. Malignant hypertension and hypertensive emergencies. Journal of the American Society of Nephrology: JASN. 1998;9(1):133–42.
Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002;347(16):1256–61.
Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341(8):577–85.
• Szczech LA, Granger CB, Dasta JF, Amin A, Peacock WF, McCullough PA, et al. Acute kidney injury and cardiovascular outcomes in acute severe hypertension. Circulation 2010;121(20):2183–91. This study measured the association between baseline chronic kidney disease, acute kidney injury, and outcome in patients hospitalized with acute severe hypertension. The results demonstrate that any degree of acute kidney injury is associated with a greater risk of morbidity and mortality.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McKie, P.M., Ichiki, T. & Burnett, J.C. M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy. Curr Hypertens Rep 14, 62–69 (2012). https://doi.org/10.1007/s11906-011-0244-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-011-0244-5